AU2022205678A1 - Fused quadracyclic compounds, compositions and uses thereof - Google Patents

Fused quadracyclic compounds, compositions and uses thereof Download PDF

Info

Publication number
AU2022205678A1
AU2022205678A1 AU2022205678A AU2022205678A AU2022205678A1 AU 2022205678 A1 AU2022205678 A1 AU 2022205678A1 AU 2022205678 A AU2022205678 A AU 2022205678A AU 2022205678 A AU2022205678 A AU 2022205678A AU 2022205678 A1 AU2022205678 A1 AU 2022205678A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
optionally substituted
mmol
alkylaminoalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022205678A
Other languages
English (en)
Inventor
Michael H. Serrano-Wu
Zhixiong Ye
Weihong Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tabomedex Biosciences Inc
Original Assignee
Tabomedex Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tabomedex Biosciences Inc filed Critical Tabomedex Biosciences Inc
Publication of AU2022205678A1 publication Critical patent/AU2022205678A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2022205678A 2021-01-11 2022-01-10 Fused quadracyclic compounds, compositions and uses thereof Pending AU2022205678A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021071062 2021-01-11
CNPCT/CN21/71062 2021-01-11
PCT/US2022/011824 WO2022150707A1 (en) 2021-01-11 2022-01-10 Fused quadracyclic compounds, compositions and uses thereof

Publications (1)

Publication Number Publication Date
AU2022205678A1 true AU2022205678A1 (en) 2023-08-03

Family

ID=82356986

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022205678A Pending AU2022205678A1 (en) 2021-01-11 2022-01-10 Fused quadracyclic compounds, compositions and uses thereof

Country Status (11)

Country Link
US (1) US20240140958A1 (https=)
EP (1) EP4274833A4 (https=)
JP (1) JP2024504927A (https=)
KR (1) KR20230145335A (https=)
CN (1) CN118574834A (https=)
AU (1) AU2022205678A1 (https=)
BR (1) BR112023013722A2 (https=)
CA (1) CA3204167A1 (https=)
IL (1) IL304142A (https=)
MX (1) MX2023007992A (https=)
WO (1) WO2022150707A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059718B2 (en) * 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof

Also Published As

Publication number Publication date
CA3204167A1 (en) 2022-07-14
EP4274833A1 (en) 2023-11-15
IL304142A (en) 2023-09-01
MX2023007992A (es) 2023-09-27
JP2024504927A (ja) 2024-02-02
CN118574834A (zh) 2024-08-30
BR112023013722A2 (pt) 2024-01-30
WO2022150707A1 (en) 2022-07-14
KR20230145335A (ko) 2023-10-17
EP4274833A4 (en) 2025-02-19
US20240140958A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
CN107949559B (zh) 作为irak4调节剂的双环稠合杂芳基或芳基化合物
JP2025142057A (ja) 化合物、医薬組成物、ならびに化合物の調製方法及び使用方法
JP6084291B2 (ja) Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤
IL267537A (en) New transformed indulgences, processes for their preparation, pharmaceutical preparations containing them and their use in the preparation of medicines
CN115298180B (zh) 治疗或抑制急性髓细胞白血病复发的化合物
JP2012511502A (ja) ジヒドロピリミドピリミジン誘導体
WO2006006490A1 (ja) スピロ化合物
US20240308976A1 (en) Compounds that mediate protein degradation and uses thereof
EP4168114A1 (en) Small molecule modulators of il-17
CN111295380B (zh) 一种高活性csf1r抑制剂化合物
WO2019158070A1 (zh) A2a和/或a2b受体拮抗剂
WO2022089389A1 (zh) 杂环化合物及其制备方法、药物组合物和应用
AU2022205678A1 (en) Fused quadracyclic compounds, compositions and uses thereof
US12091398B2 (en) PD-L1 antagonist compound
US20250177396A1 (en) Polo-like kinase 4 (plk4) inhibitors, pharmaceutical compositions, methods of preparation and uses thereof
US10562909B2 (en) Fused quadracyclic compounds, compositions and uses thereof
JP7774579B2 (ja) ピペラジン複素環アミド尿素類を含む受容体共役タンパク質１阻害剤
AU2006334820B2 (en) Diazepinones
AU2020310296B2 (en) Glucopyranosyl derivatives and their uses
TWI902351B (zh) 嘧啶胺類nuak抑制劑及其製備方法和用途
EA052066B1 (ru) Конденсированные четырехциклические соединения, их композиции и применение
WO2024041397A1 (en) Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases
WO2025231457A1 (en) Technologies for modulating citk and cell states
CN105801563B (zh) 吡唑类衍生物及其用途
KR20240170909A (ko) AXL, c-Met 및 Mer 억제제로서 피리미딘다이온 기반 화합물 및 이의 사용 방법

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 14 JAN 2026